What's Happening?
Arima Genomics, a cancer diagnostics company, has announced a distribution partnership with Active Motif, a provider of epigenetics and multiomics solutions. Under this agreement, Active Motif will have exclusive distribution rights to Arima's Hi-C kits
and services for research applications. These kits are used for non-formalin fixed paraffin embedded (FFPE) sample types, including cell lines, blood, and fresh-frozen tissues. The partnership is part of Arima's strategy to focus on its core clinical diagnostic platform, which uses Hi-C sequencing technology to analyze the structural organization of cancer genomes. This technology underpins Arima's clinical tests, Aventa FusionPlus and Aventa Lymphoma, which detect genomic alterations in solid tumors and lymphoma.
Why It's Important?
The partnership between Arima Genomics and Active Motif is significant as it allows Arima to concentrate on advancing its clinical diagnostics platform while ensuring that researchers continue to access its Hi-C sequencing tools. This collaboration is expected to enhance the understanding of genomic alterations in cancer, potentially leading to more accurate diagnostics and personalized treatment options. By leveraging Active Motif's established commercial infrastructure and product portfolio, Arima aims to expand the reach of its technology and support advancements in cancer research. This move could ultimately improve patient outcomes by providing insights into the genetic drivers of cancer.
What's Next?
As Arima Genomics focuses on its clinical diagnostics platform, the company is likely to continue developing and refining its Hi-C sequencing technology to better detect and understand cancer-driving alterations. The partnership with Active Motif may lead to increased adoption of Arima's tools in research settings, potentially resulting in new discoveries and innovations in cancer diagnostics. Additionally, the collaboration could pave the way for future partnerships and expansions into other areas of genomic research.
